~~<i id='4F663C973D'><strike id='4F663C973D'><tt id='4F663C973D'><pre id='4F663C973D'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：entertainment 2025-10-02 11:02:23 Page View：9469

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Beyond aggravation: Constipation is an American epidemic
Next article： Medicare proposal to cover medical devices draws a mixed reaction

explore

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Prime Medicine, Myeloid Therapeutics clash over genome

AdobeThecloselywatchedgene-editingstartupPrimeMedicineisembroiledinamultimillion-dollardisputewithan

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

AwoodcutshowingtheBishopofMarseilleduringtheGreatPlagueofProvenceHultonArchive/GettyImagesOnMay25,17